Clinical Trials Logo

C04.588.274.476.411.307 clinical trials

View clinical trials related to C04.588.274.476.411.307.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00212615 Completed - Clinical trials for C04.588.274.476.411.307

XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer

Start date: February 2004
Phase: Phase 2/Phase 3
Study type: Interventional

XELOX (Capecitabine and Oxaliplatin) is an effective and convenient regimen for patients with metastatic colorectal cancer. Chronomodulated therapy may reduce toxicity. Patients will be randomized to standard XELOX (Capecitabine 1000 mg/m² in the morning and 1000 mg/m² in the evening days 1-14 and short term Oxaliplatin 130 mg/m² day 1 in 30 minutes) or chronomodulated XELOX (Capecitabine 400 mg/m² in the morning and 1600 mg/m² in the evening days 1-14 and short term Oxaliplatin 130 mg/m² day 1 in 30 minutes). Bloodsamples will be collected and frozen and later examined for potential predictive factors